Protalix BioTherapeutics Inc.. (PLX) NYSE MKT LLC
$1.26 0.01 (0.80%)
Market Cap: $92.05M
As of 03/28/24 04:00 PM EDT. Market closed.
Protalix BioTherapeutics Inc.. (PLX)
NYSE MKT LLC
$1.26
0.01 (0.80%)
Market Cap: $92.05M
As of 03/28/24 04:00 PM EDT. Market closed.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic ... read more
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa?galactosidase read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Bashan Dror | PRESIDENT AND CEO | Oct 19, 2023 | Buy | $1.40 | 64,516 | 90,484 | 132,516 | Oct 20, 2023, 06:50 AM |
Schwartz Aharon | Director | Jan 03, 2023 | Buy | $1.42 | 110,000 | 155,815 | 174,000 | Jan 05, 2023, 05:08 PM |
Bashan Dror | President and CEO | Apr 11, 2022 | Buy | $1.50 | 68,000 | 102,000 | 68,000 | Apr 13, 2022, 04:05 PM |
Dexcel Pharma Technologies Ltd. | 10% Owner | Jun 03, 2021 | Sale | $2.25 | 857,506 | 1,932,304 | 3,637,314 | Jun 03, 2021, 05:40 PM |
Dexcel Pharma Technologies Ltd. | 10% Owner | Jun 02, 2021 | Sale | $2.56 | 61,211 | 156,553 | 4,494,820 | Jun 03, 2021, 05:40 PM |
Schwartz Aharon | Director | Apr 07, 2020 | Buy | $2.43 | 64,000 | 155,264 | 64,000 | Apr 13, 2020, 04:05 PM |
Manor Moshe | President & CEO | May 16, 2017 | Buy | $0.81 | 50,000 | 40,500 | 50,000 | May 16, 2017, 09:31 AM |
Camber Capital Management LLC | 10% Owner | Dec 02, 2016 | Sale | $0.32 | 2,500,000 | 792,000 | 10,775,000 | Dec 06, 2016, 03:26 PM |
Shaaltiel Yoseph | Executive VP, R&D | Sep 15, 2016 | Option Exercise | $0.00 | 122,162 | 122 | 585,916 | Sep 16, 2016, 05:01 PM |
Maimon Yossi | Vice President & CFO | Dec 14, 2015 | Buy | $0.78 | 10,000 | 7,800 | 10,000 | Dec 15, 2015, 07:30 AM |
Camber Capital Management LLC | 10% Owner | Oct 19, 2015 | Buy | $1.00 | 4,000,423 | 4,000,436 | 13,275,000 | Oct 20, 2015, 02:18 PM |
Bronfeld Zeev | Director | Aug 13, 2014 | Sale | $2.47 | 4,400,000 | 10,868,000 | 10,066,319 | Aug 15, 2014, 04:30 PM |
Bio-Cell Ltd | 10% Owner | Aug 13, 2014 | Sale | $2.47 | 4,400,000 | 10,868,000 | 10,066,319 | Aug 15, 2014, 04:30 PM |
Akirov Alfred | Director | Aug 15, 2013 | Sale | $5.07 | 2,330 | 11,813 | 4,915,383 | Aug 16, 2013, 06:00 PM |
Akirov Alfred | Director | Aug 14, 2013 | Sale | $5.05 | 110,000 | 555,750 | 4,927,713 | Aug 16, 2013, 06:00 PM |
Akirov Alfred | Director | Mar 12, 2013 | Sale | $5.70 | 10,000 | 57,000 | 5,027,713 | Mar 14, 2013, 07:00 PM |
Akirov Alfred | Director | Mar 11, 2013 | Sale | $5.72 | 18,300 | 104,737 | 5,055,713 | Mar 12, 2013, 06:30 PM |
Akirov Alfred | Director | Mar 08, 2013 | Sale | $5.86 | 16,898 | 99,068 | 5,062,911 | Mar 12, 2013, 06:30 PM |
Akirov Alfred | Director | Mar 06, 2013 | Sale | $5.69 | 4,700 | 26,737 | 5,084,046 | Mar 08, 2013, 05:04 PM |
Akirov Alfred | Director | Mar 07, 2013 | Sale | $5.72 | 8,435 | 48,233 | 5,076,346 | Mar 08, 2013, 05:04 PM |
Shaaltiel Yoseph | Executive VP, R&D | May 02, 2012 | Sale | $7.13 | 300,000 | 2,139,000 | 463,754 | May 04, 2012, 05:14 PM |
Maimon Yossi | VP, Chief Financial Officer | May 02, 2012 | Option Exercise | $1.64 | 125,964 | 206,337 | 125,964 | May 04, 2012, 05:13 PM |
Maimon Yossi | VP, Chief Financial Officer | May 02, 2012 | Sale | $7.13 | 125,964 | 898,123 | 0 | May 04, 2012, 05:13 PM |
Aviezer David | President & CEO | May 02, 2012 | Option Exercise | $0.35 | 450,000 | 159,421 | 450,000 | May 04, 2012, 05:11 PM |
Aviezer David | President & CEO | May 02, 2012 | Sale | $7.13 | 450,000 | 3,208,500 | 0 | May 04, 2012, 05:11 PM |
Almon Einat Brill | SVP, Product Development | May 02, 2012 | Option Exercise | $1.47 | 166,848 | 246,076 | 166,848 | May 04, 2012, 05:10 PM |
Almon Einat Brill | SVP, Product Development | May 02, 2012 | Sale | $7.13 | 166,848 | 1,189,626 | 0 | May 04, 2012, 05:10 PM |
Maimon Yossi | VP, Chief Financial Officer | Oct 07, 2010 | Option Exercise | $9.73 | 7,769 | 75,592 | 0 | Oct 08, 2010, 04:10 PM |
Maimon Yossi | VP, Chief Financial Officer | Oct 07, 2010 | Option Exercise | $0.97 | 77,769 | 75,591 | 0 | Oct 08, 2010, 04:10 PM |
Maimon Yossi | VP, Chief Financial Officer | Oct 07, 2010 | Sale | $9.67 | 70,000 | 676,900 | 0 | Oct 08, 2010, 04:10 PM |
Almon Einat Brill | VP, Product Development | Oct 06, 2010 | Option Exercise | $0.97 | 70,000 | 68,040 | 0 | Oct 06, 2010, 08:21 PM |
Almon Einat Brill | VP, Product Development | Oct 05, 2010 | Sale | $9.08 | 20,000 | 181,600 | 0 | Oct 06, 2010, 08:21 PM |
Almon Einat Brill | VP, Product Development | Oct 04, 2010 | Sale | $9.02 | 35,000 | 315,700 | 0 | Oct 06, 2010, 08:21 PM |
Almon Einat Brill | VP, Product Development | Oct 06, 2010 | Sale | $9.29 | 15,000 | 139,350 | 0 | Oct 06, 2010, 08:21 PM |
Maimon Yossi | VP, Chief Financial Officer | Sep 07, 2010 | Option Exercise | $0.97 | 70,000 | 68,040 | 0 | Sep 08, 2010, 04:34 PM |
Maimon Yossi | VP, Chief Financial Officer | Sep 07, 2010 | Sale | $8.16 | 31,500 | 257,040 | 0 | Sep 08, 2010, 04:34 PM |
Maimon Yossi | VP, Chief Financial Officer | Sep 03, 2010 | Sale | $8.00 | 38,500 | 308,000 | 0 | Sep 08, 2010, 04:34 PM |
Almon Einat Brill | VP, Product Development | Sep 07, 2010 | Option Exercise | $0.92 | 50,000 | 45,884 | 0 | Sep 08, 2010, 04:30 PM |
Almon Einat Brill | VP, Product Development | Sep 07, 2010 | Sale | $8.16 | 22,500 | 183,600 | 0 | Sep 08, 2010, 04:30 PM |
Almon Einat Brill | VP, Product Development | Sep 03, 2010 | Sale | $8.00 | 27,500 | 220,000 | 0 | Sep 08, 2010, 04:30 PM |
Shaaltiel Yoseph | Executive VP, R&D | Aug 06, 2010 | Sale | $7.00 | 4,619 | 32,333 | 763,754 | Aug 09, 2010, 05:00 PM |
Shaaltiel Yoseph | Executive VP, R&D | Aug 05, 2010 | Sale | $7.00 | 48,408 | 338,856 | 768,373 | Aug 09, 2010, 05:00 PM |
Owner | Relationship | Date | Value($) |
Bashan Dror | PRESIDENT AND CEO | 10/19/2023 | 90,484 |
Schwartz Aharon | Director | 01/03/2023 | 155,815 |
Bashan Dror | President and CEO | 04/11/2022 | 102,000 |
Dexcel Pharma Technologies Ltd. | 10% Owner | 06/03/2021 | 1,932,304 |
Dexcel Pharma Technologies Ltd. | 10% Owner | 06/02/2021 | 156,553 |
Schwartz Aharon | Director | 04/07/2020 | 155,264 |
Manor Moshe | President & CEO | 05/16/2017 | 40,500 |
Camber Capital Management LLC | 10% Owner | 12/02/2016 | 792,000 |
Shaaltiel Yoseph | Executive VP, R&D | 09/15/2016 | 122 |
Maimon Yossi | Vice President & CFO | 12/14/2015 | 7,800 |
Camber Capital Management LLC | 10% Owner | 10/19/2015 | 4,000,436 |
Bronfeld Zeev | Director | 08/13/2014 | 10,868,000 |
Bio-Cell Ltd | 10% Owner | 08/13/2014 | 10,868,000 |
Akirov Alfred | Director | 08/15/2013 | 11,813 |
Akirov Alfred | Director | 08/14/2013 | 555,750 |
Akirov Alfred | Director | 03/12/2013 | 57,000 |
Akirov Alfred | Director | 03/11/2013 | 104,737 |
Akirov Alfred | Director | 03/08/2013 | 99,068 |
Akirov Alfred | Director | 03/06/2013 | 26,737 |
Akirov Alfred | Director | 03/07/2013 | 48,233 |
Shaaltiel Yoseph | Executive VP, R&D | 05/02/2012 | 2,139,000 |
Maimon Yossi | VP, Chief Financial Officer | 05/02/2012 | 206,337 |
Maimon Yossi | VP, Chief Financial Officer | 05/02/2012 | 898,123 |
Aviezer David | President & CEO | 05/02/2012 | 159,421 |
Aviezer David | President & CEO | 05/02/2012 | 3,208,500 |
Almon Einat Brill | SVP, Product Development | 05/02/2012 | 246,076 |
Almon Einat Brill | SVP, Product Development | 05/02/2012 | 1,189,626 |
Maimon Yossi | VP, Chief Financial Officer | 10/07/2010 | 75,592 |
Maimon Yossi | VP, Chief Financial Officer | 10/07/2010 | 75,591 |
Maimon Yossi | VP, Chief Financial Officer | 10/07/2010 | 676,900 |
Almon Einat Brill | VP, Product Development | 10/06/2010 | 68,040 |
Almon Einat Brill | VP, Product Development | 10/05/2010 | 181,600 |
Almon Einat Brill | VP, Product Development | 10/04/2010 | 315,700 |
Almon Einat Brill | VP, Product Development | 10/06/2010 | 139,350 |
Maimon Yossi | VP, Chief Financial Officer | 09/07/2010 | 68,040 |
Maimon Yossi | VP, Chief Financial Officer | 09/07/2010 | 257,040 |
Maimon Yossi | VP, Chief Financial Officer | 09/03/2010 | 308,000 |
Almon Einat Brill | VP, Product Development | 09/07/2010 | 45,884 |
Almon Einat Brill | VP, Product Development | 09/07/2010 | 183,600 |
Almon Einat Brill | VP, Product Development | 09/03/2010 | 220,000 |
Shaaltiel Yoseph | Executive VP, R&D | 08/06/2010 | 32,333 |
Shaaltiel Yoseph | Executive VP, R&D | 08/05/2010 | 338,856 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 3,457,734 | 0.00016% | 8.89% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 724,575 | 0.00013% | 3.48% | Other |
RENAISSANCE TECHNOLOGIES LLC | 665,600 | 0.00183% | 7.16% | Other |
SCULPTOR CAPITAL LP | 37,000 (Put) | 0.00139% | No change | Event Driven |
SCULPTOR CAPITAL LP | 37,000 | 0.00139% | No change | Event Driven |
Period of Report: 12/31/2023
10-K/10-Q Filings: View